In DM-CHD models, Blimp-1 decreases markers of oxidative stress and atherosclerotic plaque formation, thus offering a therapeutic target for diseases associated with chronic inflammation and oxidative damage [10]. The gene discussed is PRDM1; the disease is diabetes mellitus.